

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: KANEH BOSM BIOTECHNOLOGY INC. (formerly Anexco Resources Ltd.) (the "Issuer").

Trading Symbol: KBB

Number of Outstanding Listed Securities: 16,064,971

Date: July 6, 2015

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 6, 2015, the Company delivered the first two BioCanna ADM kiosks to MedSmart Dispensary Inc. Deployment of the kiosks to their ultimate retail locations will take place over the next few weeks. All aspects of the BioCanna ADM software platform including point-of-sale management systems, inventory

control, ID evaluation and verification, and remote troubleshooting and repair capacities have been thoroughly tested and examined.

The BioCanna ADM retail system offers a solution to many of the concerns related to controlling access to ensure that only properly identified and qualified clients can obtain marijuana products. With strict regulations in place throughout the North American cannabis market, the BioCanna ADM could offer cannabis retailers a means to meet and surpass regulated requirements. The BioCanna ADM retail system is unique in this sector, as it encompasses the five crucial elements identified by Neill Franklin, executive director of LEAP, for safe, reliable and successful automated cannabis retail. Those elements are:

- Access control (no minors or unprescribed patients);
- Purchase volume control (monthly or daily quantity limits);
- Secure storage of product (climate-controlled and theft proof);
- Transactional oversight by regulators via software monitoring;
- A proven record in a controlled substance/products environment.

Presently, there are more than 2,000 of this type of kiosk operating across Western Europe, with many in the retail pharmaceutical dispensing marketplace. The BioCanna ADM has been field tested and proven in a controlled substance environment, such as retail pharmaceuticals in both prescription and over-the-counter products.

The initial lease agreement with MedSmart specifies that the lessee pay a deposit of \$1,000 (U.S.) per kiosk upon execution of the contract for a minimum initial lease term of 12 months. Furthermore, MedSmart will pay Kaneh Bosm a \$2.50 fee per transaction to be paid monthly.

2. Provide a general overview and discussion of the activities of management.

The Company continues to push forward with its LP application with the Penticton Indian Band. Presently the 120-days settlement period of the joint venture agreement has been expired. However, the negotiation of the LP application is on-going.

Currently, the Company is re-evaluating their Canadian focus.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship:
None.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
None.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
None.
8. Describe the acquisition of new customers or loss of customers.
Not applicable.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
There were no new developments.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
There were no employee activities.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
There are no legal proceedings.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
None.

14. Provide details of any securities issued and options or warrants granted.
None.
15. Provide details of any loans to or by Related Persons.
None.
16. Provide details of any changes in directors, officers or committee members.
None.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
There are no trends specific to the Issuer at this time.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 6, 2015

Name of Director or Senior Officer

Rudy de Jonge

"Rudy de Jonge"

CEO, Director

Issuer Details Name of Issuer Kaneh Bosm Biotechnology Inc.	For Month End June, 2015	Date of Report YY/MM/DD 15/07/06
Issuer Address #810 – 675 W. Hastings Street		
City/Province/Postal Code Vancouver, BC V6N 1B2	Issuer Fax No. (604)684-2349	Issuer Telephone No. (604)782.4191
Contact Name Rudy de Jonge	Contact Position CEO, Director	Contact Telephone No. (604)782.4191
Contact Email Address rudydejonge@hotmail.com	Web Site Address NA	